News | August 10, 2025
Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Delivers robust earnings performance, successfully navigating a dynamic environment
Bayer expects 2025 to be the most difficult year of its turnaround
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Subscribe To Our Newsletter & Stay Updated
